Head-to-head comparison
| Property | MK-677 | Sermorelin |
|---|---|---|
| Category | Muscle & Growth | Muscle & Growth |
| Legal Status | Unregulated | Reclassification Pending |
| Primary Route | oral | subcutaneous |
| Half-life | ~24 hours | ~10-20 minutes |
| Mol. Weight | 528.67 Da | 3,357.88 Da |
| Side Effects | Increased appetite / intense hunger, Water retention and edema, Insulin resistance (glucose elevation) | Injection site reactions, Facial flushing, Headache |
Key differences
- Receptor pathway: MK-677 acts on the ghrelin receptor (GHS-R); sermorelin acts on the GHRH receptor. These are entirely separate signaling pathways.
- Administration: MK-677 is orally active (pill/capsule); sermorelin requires subcutaneous injection.
- GH release pattern: MK-677 produces sustained 24-hour GH/IGF-1 elevation; sermorelin produces acute, pulsatile GH spikes that mimic natural secretion.
- Half-life: MK-677 has a 24-hour duration of action; sermorelin has a half-life of 10–20 minutes.
- Appetite effects: MK-677 significantly increases appetite via ghrelin pathway activation; sermorelin has minimal appetite effects.
- FDA history: Sermorelin was previously FDA-approved as Geref (withdrawn for commercial reasons); MK-677 has never been FDA-approved.
- Metabolic effects: MK-677 can increase fasting glucose and decrease insulin sensitivity; sermorelin has a more favorable metabolic profile with fewer effects on glucose homeostasis.
The verdict
MK-677 offers oral convenience and sustained GH/IGF-1 elevation, making it attractive for those avoiding injections. Sermorelin provides a more physiological, pulsatile GH pattern with fewer metabolic side effects and prior FDA approval history. For GH optimization with minimal side effects, sermorelin is generally preferred. For oral convenience and sustained IGF-1 elevation, MK-677 is more practical. The appetite increase and insulin sensitivity concerns with MK-677 are significant considerations.
Frequently asked questions
MK-677 produces more sustained GH/IGF-1 elevation due to its 24-hour duration, while sermorelin produces acute pulsatile GH release that more closely mimics natural patterns. Which is better depends on whether sustained elevation or physiological pulsatility is the priority.
They act on different receptor systems (ghrelin vs GHRH), so combining them could theoretically produce synergistic GH release. However, this would increase the total GH stimulus substantially. No clinical studies have evaluated this specific combination.
Yes, MK-677 has documented effects on fasting glucose and insulin sensitivity that are more pronounced than sermorelin. This is an important consideration for individuals with diabetes risk factors or metabolic concerns.
MK-677 is significantly more convenient — it is an oral pill taken once daily, requiring no injections or refrigeration. Sermorelin requires daily subcutaneous injection and cold chain storage.
Yes, sermorelin was previously FDA-approved as Geref for diagnosing growth hormone deficiency. It was withdrawn from the market for commercial (business) reasons, not safety concerns. This gives it a more established safety profile than MK-677, which has never been FDA-approved.